修正的供者淋巴细胞输注研究进展

Research progress of modified donor lymphocyte infusion

造血干细胞移植（HSCT）已经成为恶性血液病的重要治疗手段。然而，移植后疾病复发可显著降低患者的长期生存率。修正的供者淋巴细胞输注（MDLI），输注的是经粒细胞集落刺激因子（G-SF）动员的外周造血干细胞，而非静止状态的淋巴细胞。该方法能够减少供者淋巴细胞输注（DLI）后相关的移植物抗宿主病（GVHD）及复杂性血细胞减少，同时保留或者增强移植物抗肿瘤效应（GVT），因此MDLI已经广泛用于恶性血液病移植后复发的治疗。笔者拟就MDLI的作用机制、临床适应证、输注剂量、输注时机、间隔时间、疗效评估等进行综述。

Hematopoietie stem cell transplantation（HSCT） has become an important means to treat hematologic malignancies. However disease relapse after transplantation significantly reduced the long-term survival of patients. Modified donor lymphocyte infusion（MDLI） is infused peripheral blood stem cells which mobilization with granuloeyte colony stimulating faetor （G-CSF）, rather than a static state of lymphoeytes. This method has been widely used in the treatment of hematologic malignancies relapse after transplantation, which can reduce donor lymphocyte infusion（DLI） infusion-related graft-versus-host disease（GVHD） and decrease amount of blood eells, meanwhile it can preserve or enhance the effect of graft versus tumour （GVT）. This paper is proposed to review the mechanism, indication, dose infusion, infusion timing interval and efficacy assessment of MDLI.